Showing results (91-100 of 188) with videos related to
Sort By:
Pageof 19
Journal of the National Cancer Institute|November 2, 1988
Hydroxyurea and etoposide: in vitro synergy and phase I clinical trialM J Ratain, R L Schilsky, B R Wojack, et al.Pharmacogenetics|February 1, 1996
Individualized dosing of amonafide based on a pharmacodynamic model incorporating acetylator phenotype and genderM J Ratain, R Mick, L Janisch, et al.Cancer|October 1, 1994
Prognostic factors for survival in patients treated in phase I clinical trialsL Janisch, R Mick, R L Schilsky, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1997
Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patientsE Gupta, R Mick, J Ramirez, et al.Leukemia|April 1, 1987
Changes in peripheral blood and bone marrow specimens during and after alpha 2b-interferon therapy for hairy cell leukemiaR G Bardawil, M J Ratain, H M Golomb, et al.Cancer Chemotherapy and Pharmacology|June 15, 2000
Development of a schedule-dependent population pharmacodynamic model for rhizoxin without quantitation of plasma concentrationsB C Goh, G F Fleming, L Janisch, et al.Cancer Chemotherapy and Pharmacology|June 10, 1998
Phase I clinical and pharmacokinetic study of oral 9-aminocamptothecin (NSC-603071)S Mani, L Iyer, L Janisch, et al.Clinical Pharmacology and Therapeutics|November 1, 1991
Paradoxical relationship between acetylator phenotype and amonafide toxicityM J Ratain, R Mick, F Berezin, et al.Cancer|June 15, 1987
Flow cytometry in hairy cell leukemia before and during interferon alfa-2b therapyE E Vokes, M A Bitter, M J Ratain, et al.Blood|March 1, 1985
Treatment of hairy cell leukemia with recombinant alpha 2 interferonM J Ratain, H M Golomb, J W Vardiman, et al.Pageof 19